Nuwellis, Inc. has submitted a 510(k) premarket notification to the FDA to expand the use of its Aquadex SmartFlow System to pediatric patients weighing as little as 5 kg, down from the current 20 kg limit. This move is supported by clinical data including the ULTRA-Peds Registry, which shows the system's safety and effectiveness in smaller children. Approval would allow broader use in pediatric care, offering a precise fluid management option for vulnerable young patients. The submission follows positive regulatory discussions and aims to grow Nuwellis' pediatric market presence.
Nuwellis Inc. has a market cap of $2.14 million and a trading volume of 75,463 shares on Pluang as of Nov 05, 2026 20:12 WIB. The stock price is USD 5.15, down 2.28% in the last day, with a high sell order activity of 92%. This trading activity reflects investor caution despite the company's efforts to expand its pediatric market with the FDA submission.
